Nordwand Advisors’s AstraZeneca AZN Stock Holding History

Nordwand Advisors’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-200	Closed	-$29.4K	–	177
2025 Q1	$29.4K	Hold	200	–	–	0.01%	59
2024 Q4	$26.2K	Hold	200	–	–	0.01%	64
2024 Q3	$31.2K	Hold	200	–	–	0.01%	63
2024 Q2	$31.2K	Hold	200	–	–	0.01%	80
2024 Q1	$27.1K	Sell	200 -89	-31%	-$11.8K	0.01%	96
2023 Q4	$38.9K	Buy	289 +89	+45%	+$11.6K	0.01%	75
2023 Q3	$27.1K	Hold	200	–	–	0.01%	75
2023 Q2	$28.6K	Hold	200	–	–	﹤0.01%	73
2023 Q1	$27.8K	Sell	200 -10,043	-98%	-$1.35M	﹤0.01%	78
2022 Q4	$1.39M	Buy	+10,243	New	+$1.28M	0.17%	33

Other funds holding AZN

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Sanders Capital West Palm Beach, Florida $99.8B AUM 47.9% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Nordwand Advisors's AZN Position: Q2 2025 in Review

Nordwand Advisors sold out of AstraZeneca (AZN) in Q2 2025, closing a stake of 200 shares — an estimated $29.4K sold.

Nordwand Advisors first reported a position in AZN in Q4 2022 and held it in 10 quarters. The position peaked at $1.39M in Q4 2022. 1,222 funds tracked by Wall St. Rank hold AZN as of Q2 2025.

Nordwand Advisors reported no remaining AstraZeneca position as of Q2 2025 after selling out during the quarter.
Nordwand Advisors sold 200 AstraZeneca shares in Q2 2025, an estimated $29.4K.
Nordwand Advisors first reported a position in AstraZeneca in Q4 2022 and held it in 10 quarters.
Nordwand Advisors's AstraZeneca position peaked at $1.39M in Q4 2022.
1,222 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2025.

Based on Nordwand Advisors's 13F filing for Q2 2025, filed 11 Aug 2025.